Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,881.00GBp
15 Dec 2017
Change (% chg)

-3.50 (-0.07%)
Prev Close
4,884.50
Open
4,889.00
Day's High
4,889.00
Day's Low
4,846.50
Volume
3,606,336
Avg. Vol
2,466,307
52-wk High
5,585.07
52-wk Low
4,136.50

Latest Key Developments (Source: Significant Developments)

Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates
Wednesday, 13 Dec 2017 07:05am EST 

Dec 13 (Reuters) - Iovance Biotherapeutics Inc ::IOVANCE BIOTHERAPEUTICS ANNOUNCES MANUFACTURING DECISION, PROVIDES CLINICAL UPDATES AND HIGHLIGHTS PIPELINE EXPANSION AT ANALYST DAY 2017.IOVANCE BIOTHERAPEUTICS - SELECTED ITS GEN 2 MANUFACTURING PROCESS FOR ALL THREE PHASE 2 TRIALS, ALL FUTURE TIL CLINICAL DEVELOPMENT.IOVANCE - PROTOCOLS FOR 3 EXISTING STUDIES HAVE BEEN AMENDED TO ALLOW ENROLLMENT OF NEW PATIENTS WITH TIL MANUFACTURED WITH GEN 2 PROCESS.IOVANCE - COHORT 1 OF C-144-01 MELANOMA STUDY WILL BE CLOSED AND NEW PATIENTS WILL BE ENROLLED IN COHORT 2.IOVANCE - PHASE 2 STUDY IN PD-1 AND PD-L1 NAÏVE NSCLC PATIENTS WILL INITIATE IN H1 2018.IOVANCE - MD ANDERSON CANCER CENTER TO INITIATE 2 BASKET STUDIES IN SARCOMA & PLATINUM RESISTANT OVARIAN CANCER.IOVANCE - CO RETAINS RIGHTS TO MDA PRECLINICAL RESEARCH IN EXPANDING UNDERSTANDING OF TIL, RELATED INTELLECTUAL PROPERTY.  Full Article

Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402
Thursday, 7 Dec 2017 08:30am EST 

Dec 7 (Reuters) - Pieris Pharmaceuticals Inc ::PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402.PIERIS PHARMACEUTICAL - THE PHASE 1 STUDY IS BEING DEVELOPED AS PART OF PIERIS' STRATEGIC ALLIANCE WITH ASTRAZENECA.PIERIS PHARMACEUTICALS - DOSING FIRST SUBJECT IN TRIAL FOR PRS-060/AZD1402 BY YEAR END.  Full Article

Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant
Thursday, 7 Dec 2017 06:50am EST 

Dec 7 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS COMMENCES PIVOTAL STUDY FOR FULVESTRANT.EAGLE PHARMACEUTICALS- ANTICIPATES COMPLETION OF FULVESTRANT STUDY WITHIN TWELVE MONTHS, AND AN EXPECTED NDA FILING IN Q4 OF 2018.  Full Article

G1 Therapeutics And AstraZeneca Enter Clinical Trial Collaboration In Non-Small Cell Lung Cancer
Tuesday, 28 Nov 2017 07:00am EST 

Nov 28 (Reuters) - G1 Therapeutics Inc ::G1 THERAPEUTICS AND ASTRAZENECA ENTER CLINICAL TRIAL COLLABORATION IN NON-SMALL CELL LUNG CANCER.- ‍FINANCIAL TERMS OF NON-EXCLUSIVE COLLABORATION HAVE NOT BEEN DISCLOSED​.G1 THERAPEUTICS - ‍COLLABORATION TO EVALUATE ASTRAZENECA'S EGFR TYROSINE KINASE INHIBITOR TAGRISSO IN COMBINATION WITH G1'S ORAL CDK4/6 INHIBITOR G1T38​.G1 THERAPEUTICS SAYS IT WILL SPONSOR AND CONDUCT A PHASE 1B/2 STUDY IN COLLABORATION WITH ASTRAZENECA IN PATIENTS WITH NSCLC​.SAYS ‍PLANS TO INITIATE TRIAL IN Q1 OF 2018​.  Full Article

Astrazeneca Plc says EMA accepts Tagrisso submission for 1st-line nsclc
Tuesday, 28 Nov 2017 02:00am EST 

Nov 28 (Reuters) - ASTRAZENECA PLC ::‍EMA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLC​.‍EUROPEAN MEDICINES AGENCY ACCEPTS REGULATORY SUBMISSION FOR TAGRISSO IN 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER​.  Full Article

Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca‍​
Friday, 17 Nov 2017 02:38am EST 

Nov 17 (Reuters) - ALMIRALL SA ::ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA‍​.  Full Article

Astrazeneca says U.S. FDA approved fasenra (benralizumab) for severe eosinophilic asthma
Tuesday, 14 Nov 2017 06:38pm EST 

Nov 14 (Reuters) - Astrazeneca Plc :Astrazeneca - co, Medimmune, announced that U.S. FDA approved fasenra (benralizumab) for severe eosinophilic asthma.Astrazeneca - FDA approval based on phase III programme showing up to 51 pct reduction in asthma exacerbations & 75 pct reduction in daily oral steroid use‍​.  Full Article

Astrazeneca says EU approves new indication for Faslodex in combination with palbociclib
Tuesday, 14 Nov 2017 07:24am EST 

Nov 14 (Reuters) - Astrazeneca Plc :FASLODEX (FULVESTRANT) RECEIVES EU APPROVAL FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB1.  Full Article

Astrazeneca says Benralizumab receives Positive EU CHMP opinion
Friday, 10 Nov 2017 06:35am EST 

Nov 10 (Reuters) - ASTRAZENECA PLC ::BENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMA.‍ANNOUNCED THAT CHMP OF EUROPEAN MEDICINES AGENCY HAS ADOPTED POSITIVE OPINION, RECOMMENDING MARKETING AUTHORISATION OF BENRALIZUMAB​.  Full Article

AstraZeneca CEO committed to dividend
Thursday, 9 Nov 2017 07:49am EST 

Nov 9 (Reuters) - AstraZeneca CEO Pascal Soriot says::* committed to dividend "today, tomorrow and day after".  Full Article

Photo

GSK's new pharma head on lookout for cancer deals to boost pipeline

LONDON GlaxoSmithKline will scout for deal opportunities in cancer medicine, as well as immunology, as the drugmaker seeks to rebuild its presence in oncology, its new head of pharmaceuticals told Reuters.